Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer.

Novel multi-target-directed ligands were designed by replacing the inner dipiperidino function of 3 with less flexible or completely rigid moieties to obtain compounds endowed with multiple biological properties that might be relevant to Alzheimer's disease. 15 was the most interesting, inhibiting AChE in the nanomolar range and inhibiting AChE-induced and self-promoted beta-amyloid aggregation in the micromolar range.

[1]  J L Sussman,et al.  Structure and dynamics of the active site gorge of acetylcholinesterase: Synergistic use of molecular dynamics simulation and X‐ray crystallography , 1994, Protein science : a publication of the Protein Society.

[2]  Claudia Linker,et al.  Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme , 1996, Neuron.

[3]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[4]  M L Bolognesi,et al.  Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. , 1998, Journal of medicinal chemistry.

[5]  C. Sotiriou-Leventis,et al.  A facile synthesis of 2,7‐diazapyrene , 2000 .

[6]  N. Ariel,et al.  Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. , 2000, Acta crystallographica. Section D, Biological crystallography.

[7]  C. Soto,et al.  Beta‐sheet breaker strategy for the treatment of Alzheimer's disease , 2002 .

[8]  Yvain Nicolet,et al.  Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products* , 2003, Journal of Biological Chemistry.

[9]  A. Cavalli,et al.  Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine. , 2003, Journal of medicinal chemistry.

[10]  V. Andrisano,et al.  beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. , 2003, Biochemical pharmacology.

[11]  A. Cavalli,et al.  3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. , 2003, Journal of medicinal chemistry.

[12]  V. Andrisano,et al.  Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties. , 2004, Journal of medicinal chemistry.

[13]  Anabella Villalobos,et al.  Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. , 2004, European journal of pharmacology.

[14]  A. Cavalli,et al.  Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. , 2004, Journal of medicinal chemistry.

[15]  V. Andrisano,et al.  Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation. , 2005, Journal of medicinal chemistry.

[16]  Ettore Novellino,et al.  Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. , 2005, Journal of medicinal chemistry.

[17]  Brian J Bacskai,et al.  In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. , 2005, Angewandte Chemie.

[18]  Andrea Cavalli,et al.  A Comparative Study on the Application of Hierarchical-Agglomerative Clustering Approaches to Organize Outputs of Reiterated Docking Runs , 2006, J. Chem. Inf. Model..

[19]  Ana Martínez,et al.  Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease , 2006, Expert opinion on investigational drugs.

[20]  W. Geldenhuys,et al.  Multifunctional drugs with different CNS targets for neuropsychiatric disorders , 2006, Journal of neurochemistry.

[21]  O. Livnah,et al.  Butyrylcholinesterase attenuates amyloid fibril formation in vitro. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Vildan Alptüzün,et al.  Targeting acetylcholinesterase to treat neurodegeneration , 2007, Expert opinion on therapeutic targets.

[23]  M. Decker.  Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties. , 2007, Mini reviews in medicinal chemistry.

[24]  Christopher Clark,et al.  Disease-modifying therapies for Alzheimer disease , 2007, Neurology.

[25]  Maurizio Recanatini,et al.  Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. , 2007, Journal of medicinal chemistry.

[26]  Maurizio Recanatini,et al.  A small molecule targeting the multifactorial nature of Alzheimer's disease. , 2007, Angewandte Chemie.

[27]  N. Relkin.  Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer’s disease , 2007, Expert review of neurotherapeutics.

[28]  Yun Tang,et al.  Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. , 2008, Journal of medicinal chemistry.

[29]  Multi‐Target‐Direct Ligands to Combat Neurodegenerative Diseases , 2008 .